MARKET

SERA

SERA

SERA PROGNOSTICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.13
+0.78
+8.34%
After Hours: 10.13 0 0.00% 16:00 09/24 EDT
OPEN
9.10
PREV CLOSE
9.35
HIGH
10.30
LOW
9.09
VOLUME
123.14K
TURNOVER
--
52 WEEK HIGH
15.50
52 WEEK LOW
7.61
MARKET CAP
310.98M
P/E (TTM)
-13.3712
1D
5D
1M
3M
1Y
5Y
BRIEF-Sera Prognostics Inc To Be Added To Russell 2000 Index
reuters.com · 5d ago
Sera Prognostics to be Added to Russell 2000 Index
SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announ...
GlobeNewswire · 5d ago
Sera Prognostics Announces Publication of Health Economic Analysis Supporting PreTRM® Test-and-Treat Strategy to Improve Maternal and Infant Health
Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs Positive impact on preterm births, neonatal intensive care admissions, overall hospital length ...
GlobeNewswire · 09/14 12:00
Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announ...
GlobeNewswire · 09/13 12:00
BRIEF-Sera Prognostics Inc QTRLY Net Loss Per Share, Basic And Diluted $3.17
reuters.com · 08/30 21:18
Sera Prognostics Q2 Loss Widens from Year Ago
MT Newswires · 08/30 17:10
-- Earnings Flash (SERA) SERA PROGNOSTICS Reports Q2 Revenue $20,000
MT Newswires · 08/30 16:16
Sera Prognostics Highlights Publication Of PREVENT-PTB Study In American Journal Of Perinatology
 Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the
Benzinga · 08/17 12:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SERA. Analyze the recent business situations of SERA PROGNOSTICS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SERA stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 0
Institutional Holdings: 0
% Owned: 0.00%
Shares Outstanding: 30.70M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Business Support Services
-0.72%
Professional & Commercial Services
-0.23%
Key Executives
Chairman/President/Chief Executive Officer/Director
Gregory Critchfield
Chief Financial Officer/Primary Contact
Jay Moyes
Chief Information Officer
Robert Harrison
Chief Scientific Officer
Jay Boniface
Executive Officer
Nadia Altomare
No Data
About SERA
Sera Prognostics, Inc. is a women’s health diagnostic company that is focused on utilizing its proteomics and bioinformatics platform to discover, develop and commercialize clinically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The Company's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.

Webull offers kinds of Sera Prognostics Inc stock information, including NASDAQ:SERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SERA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SERA stock methods without spending real money on the virtual paper trading platform.